GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed  Additional data evaluating GEO-CM04S1 as ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Reports 2024 Year-End Financial Results and Provides Business Update 27.03.2025 / 21:06 CET/CEST The issuer is solely responsible for the ...

Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune checkpoint inhibitors. These treatments, which ...

Title: A TGFß-directed immune-modulatory vaccine induces T cell activation and drives antitumor activity by modulating the tumor microenvironment Abstract Number: 2257 Date and Time: Monday, April 28, ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...